IMBRS23027_Falkson_J2J-MC-JZLH - EMBER-4
Basic Study Information
Purpose:
The main purpose of this study is to measure how well imlunestrant works compared
to standard hormone therapy in participants with early breast cancer that is estrogen
receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants
must have already taken endocrine therapy for two to five years and must have a higher-than-average
risk for their cancer to return. Study participation could last up to 10 years.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Carla Falkson
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search